Phase 1 Clinical Evaluation of the CCR2 Antagonist CCX872-B

被引：0
|
作者：
Bekker, Pirow
Charvat, Trevor
Miao, Shichang
Lohr, Lisa
Sullivan, Timothy
Miao, Zhenhua
Powers, Jay
Jaen, Juan
Schall, Thomas J.
机构：
来源：
DIABETES | 2013年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1126-P
引用
收藏
页码：A292 / A293
页数：2
相关论文
共 50 条
  • [21] Eotaxin: A CCR2 antagonist and a CCR5 agonist on human monocytes
    Ogilvie, P
    Bardi, G
    Loetscher, P
    Baggiolini, M
    Uguccioni, M
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2000, 115 (03) : 532 - 532
  • [22] Evaluation of a small molecule CCR2 antagonist in a rat model of rheumatoid arthritis.
    Brodmerkel, CN
    Collins, R
    Hall, L
    Hertel, D
    Stewart, R
    Wang, A
    Xue, CB
    Diamond, S
    Friedman, S
    Vaddi, K
    ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S369 - S369
  • [23] Pharmacokinetic and Pharmacodynamic Evaluation of the Novel CCR1 Antagonist CCX354 in Healthy Human Subjects: Implications for Selection of Clinical Dose
    Dairaghi, D. J.
    Zhang, P.
    Wang, Y.
    Seitz, L. C.
    Johnson, D. A.
    Miao, S.
    Ertl, L. S.
    Zeng, Y.
    Powers, J. P.
    Pennell, A. M.
    Bekker, P.
    Schall, T. J.
    Jaen, J. C.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 (05) : 726 - 734
  • [24] Characterization of the CCR2 chemokine receptor: Functional CCR2 receptor expression in B cells
    Frade, JMR
    Mellado, M
    del Real, G
    Gutierrez-Ramos, JC
    Lind, P
    Martinez, C
    JOURNAL OF IMMUNOLOGY, 1997, 159 (11): : 5576 - 5584
  • [25] The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial
    de Zeeuw, Dick
    Bekker, Pirow
    Henkel, Elena
    Hasslacher, Christopher
    Gouni-Berthold, Ioanna
    Mehling, Heidrun
    Potarca, Antonia
    Tesar, Vladimir
    Heerspink, Hiddo J. Lambers
    Schall, Thomas J.
    LANCET DIABETES & ENDOCRINOLOGY, 2015, 3 (09): : 687 - 696
  • [26] Optimized dosing of a CCR2 antagonist for amplification of vaccine immunity
    Mitchell, Leah A.
    Hansen, Ryan J.
    Beaupre, Adam J.
    Gustafson, Daniel L.
    Dow, Steven W.
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2013, 15 (02) : 357 - 363
  • [27] Cenicriviroc, a CCR2/CCR5 antagonist, promotes the generation of type 1 regulatory T cells
    Madan, Upasna
    Verma, Bhawna
    Awasthi, Amit
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2024, 54 (07)
  • [28] A dual CCR2/CCR5 chemokine antagonist, BMS-813160?
    Norman, Peter
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2011, 21 (12) : 1919 - 1924
  • [29] Chemokine receptor 2 antagonist CCX140-B in Phase 2 for type 2 diabetes
    Sullivan, T.
    Miao, S.
    Berahovich, R.
    Zhao, N.
    Ungashe, S.
    Johnson, D.
    Bekker, P.
    Jean, J.
    Schall, T. J.
    DIABETOLOGIA, 2010, 53
  • [30] Discovery of a Potent and Orally Bioavailable CCR2 and CCR5 Dual Antagonist
    Pasternak, Alexander
    Goble, Stephen D.
    Struthers, Mary
    Vicario, Pasquale P.
    Ayala, Julia M.
    Di Salvo, Jerry
    Kilburn, Ruth
    Wisniewski, Thomas
    DeMartino, Julie A.
    Mills, Sander G.
    Yang, Lihu
    ACS MEDICINAL CHEMISTRY LETTERS, 2010, 1 (01): : 14 - 18
12345